(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AssigneeOryzon Genomics, S.A.
InventorsAlberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
Life of this patent
Estimating the term…
Abstract
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Claims26
A method of treating cancer, the method comprising administering, to a subject in need of such treatment, a compound selected from N1-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, and a salt or solvate thereof.
A method of treating cancer, the method comprising administering, to a subject in need of such treatment, a pharmaceutical composition comprising a compound selected from N1-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, and a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
A method of treating cancer, the method comprising administering, to a subject in need of such treatment, a compound selected from (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine and a salt or solvate thereof.
A method of treating cancer, the method comprising administering, to a subject in need of such treatment, a pharmaceutical composition comprising a compound selected from (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine and a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.